Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one company still healing the wounds of discontinued drug development trials. Notably, the firm discontinued trials for ARC-520, ARC-521, and ARC-AAT in 2016 and which battered its balance. However, this year looks promising as the firm just initiated Phase 1 study of ARO-APOC3.

Arrowhead expands the TRiM based pipeline to five candidates

Notably, this new drug candidate leverages the proprietary Targeted RNAi Molecule better known as TRiM. The clinical trials will examine ARO-APOC3’s ability to address hypertriglyceridemia. In particular, the drug candidate will aim to reduce apoC-III produced in the liver. According to the details of the clinical trial documents, Arrowhead will investigate ARO-APOC3 effectiveness in participants who depict elevated triglycerides.

Primarily, the outcomes of the study will help Arrowhead to formulate the development strategy better the drug candidate. Additionally, the outcomes will inform the possible regulatory paths the firm can pursue.

According to Chris Anzalone, Ph.D., president, and CEO of Arrowhead, commencement of the trials will add to their pipeline. Notably, the pipeline will now consist of five drug candidates that leverage TRiM. Interestingly, the firm assures that once the approval for Phase 1 is in place, they will go straight dosing of participants. In particular, this phase will evaluate the tolerability and safety of the various elements of the drug candidate. Arrowhead intends to use 63 volunteers for the study.

Focusing on the potential of ANGPTL3

Meanwhile, the firm reported the commencement of Phase 1 study of another drug candidate under the TRiM umbrella. The clinical study of ARO-ANG3 focuses on the treatment of metabolic disease and dyslipidemias. Notably, the firm already dosed the first batch of participants who are under examination.

In particular, the drug candidate specifically targets ANGPTL3 which, as Arrowhead observed, is “a potentially important target to address dyslipidemias, such as elevated cholesterol and triglycerides that are not well-controlled with currently available medicines, and also metabolic diseases, such as NAFLD and NASH.”

The anticipated outcomes of the clinical study will help the firm to unlock the potential of using ANGPTL3 to target metabolic diseases. Further, the outcomes will help to determine the safety and tolerability profile of various components of the drug candidate.

Kyle Dennis might be the world’s best biotech trader under 30 years old. He’s turned a $15k grubstake into over $4.1 MILLION in profits. Now, you can learn directly from Kyle and see what trades he is making in this limited-time opportunity. Learn how his “Sniper Trades” can take your trading to levels you never thought possible!